Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| First Wave BioPharma Inc | FWBI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.96 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.3335 - 59.998 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.96 | USD |
First Wave BioPharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2M | 675.00k | - | 0 | -16.1M | -23.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
First Wave BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FWBI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 2.65 | 3.0743 | 2.3335 | 2.78 | 37,939 | 0.31 | 11.70% |
| 3 Months | 8.19 | 8.19 | 2.3335 | 4.46 | 73,010 | -5.23 | -63.86% |
| 6 Months | 4.80 | 14.51 | 2.3335 | 5.35 | 475,392 | -1.84 | -38.33% |
| 1 Year | 40.00 | 59.998 | 2.3335 | 14.34 | 1,643,734 | -37.04 | -92.60% |
| 3 Years | 483.00 | 686.00 | 2.3335 | 98.16 | 1,412,739 | -480.04 | -99.39% |
| 5 Years | 483.00 | 686.00 | 2.3335 | 98.16 | 1,412,739 | -480.04 | -99.39% |
First Wave BioPharma Description
| First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. |
